key: cord-0960871-holg405a authors: Menga, Luca S.; Grieco, Domenico Luca; Rosà, Tommaso; Cesarano, Melania; Cese, Luca Delle; Berardi, Cecilia; Pintaudi, Gabriele; Tanzarella, Eloisa Sofia; Cutuli, Salvatore L.; De Pascale, Gennaro; Maggiore, Salvatore Maurizio; Antonelli, Massimo title: Dyspnea and clinical outcome in critically ill patients receiving noninvasive support for COVID-19 respiratory failure: post-hoc analysis of a randomized clinical trial date: 2021-08-19 journal: ERJ Open Res DOI: 10.1183/23120541.00418-2021 sha: 98a24c1de97c901a5e0ce3c955aa547d12426123 doc_id: 960871 cord_uid: holg405a In non-COVID 19 acute hypoxemic respiratory failure, the entity of dyspnea has been associated with severity of hypoxemia, and represents a factor predicting noninvasive ventilation (NIV) failure, the need for endotracheal intubation and mortality [1]. DLG has received payments for travel expenses by Maquet, Getinge and Air Liquide. MA has received payments for Board participation from Maquet, Air Liquide and Chiesi. DLG and MA disclose a research grant by General Electric Healthcare. The study was funded by a research grant (2017 MSD award) by the Italian Society of Anesthesia, Analgesia and Intensive Care Medicine (SIAARTI). The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Outside of the submitted work, Dr. Grieco is supported by a research grant by the European Society of Intensive Care Medicine (ESICM). In non-COVID 19 acute hypoxemic respiratory failure, the entity of dyspnea has been associated with severity of hypoxemia, and represents a factor predicting noninvasive ventilation (NIV) failure, the need for endotracheal intubation and mortality [1] . In COVID-19 respiratory failure the concept of "silent hypoxemia" has been described: this is a condition of hypoxemia without concomitant dyspnea and/or signs of respiratory distress [2] . Whether in COVID-19 patients dyspnea is related to outcome is unknown. We performed a post-hoc analysis of a multicenter randomized trial (NCT04502576) that compared helmet noninvasive ventilation and highflow nasal oxygen, aiming to assess the prevalence of dyspnea in COVID-19 patients admitted to the intensive care unit (ICU) and to determine whether this may be related to study outcomes [3] . One-hundred nine patients admitted to four ICUs and receiving noninvasive respiratory support due to COVID-19 acute hypoxemic respiratory failure (PaO 2 /FiO 2 ≤200) were analyzed. The full protocol and study procedures are described elsewhere [3] . At ICU admission, all patients were asked to rate the subjective sensation of dyspnea from 0 to 10, with 10 representing the worst symptom, through a visual analog scale [4] [5] [6] . Dyspnea was re-evaluated at 1, 6, 12, 24 and 48 hours after the initiation of the assigned treatment, which was either high-flow nasal oxygen or helmet NIV. Patients with VAS dyspnea≥4 were considered having moderate-to-severe dyspnea group, while patients with VAS dyspnea<4 were considered having mild-or-no dyspnea, as previously suggested [1] . The number of days free of advanced respiratory support (including high-flow nasal oxygen, non-invasive and invasive ventilation) within 28 days after enrollment, the proportion of patients who required endotracheal intubation within 28 days from study enrollment, the number of days free of invasive mechanical ventilation at day 28 and 60, 28-day, 60-day, in-ICU and in-hospital mortality, ICU and hospital length of stay were the analyzed outcomes. Patients with moderate-to-severe dyspnea had fewer days free of invasive ventilation day 28 and 60, longer ICU and hospital length of stay, and higher in-ICU mortality and in-hospital mortality. There was no significant difference in 28-day and 60-day mortality (Table 1 ). In this post-hoc analysis of a randomized clinical trial conducted in COVID-19 patients admitted to the ICU with moderate-to-severe hypoxemic respiratory failure and receiving a trial of noninvasive respiratory support, 52 patients (48%) showed moderate-to-severe dyspnea at ICU admission. Conversely, 57 patients (52%) had moderate-to-severe oxygenation impairment with mild or no dyspnea, possibly configuring the 'silent hypoxemia' condition. Reporting moderate-to-severe dyspnea at ICU admission was independently associated with increased need for endotracheal intubation, less respiratory support-free days, less invasive mechanical ventilation-free days at day 28 and 60, longer ICU and hospital length of stay, and higher in-ICU and in-hospital mortality. The perception of dyspnea is mediated by many physiological factors, including PaO 2 and PaCO 2 . Increases in respiratory drive and dyspnea appear only when PaO 2 falls below 60-70 mmHg and PaCO 2 is more than 39 mmHg [2, 7, 8] ; however, PaO 2 is usually maintained by clinicians above 60 mmHg for safety reasons, and PaCO 2 is commonly below 39 mmHg due to higher sensitivity of respiratory center to CO 2 stimulus in patients with acute respiratory failure [8] . Indeed, only 5 patients exhibited PaO 2 below 60 mmHg and/or PaCO 2 above 39 mmHg, and among them only 2 were not showing signs of dyspnea. In our cohort, patients that showed high-to-moderate dyspnea at enrollment had higher risk of endotracheal intubation and higher in-ICU mortality, confirming that the self-reported sensation of dyspnea is not related to hypoxemia or hypercapnia per se, but rather to the entity of pulmonary damage and to the severity of illness. In COVID-19 induced moderate-to-severe acute hypoxemic respiratory failure the presence of moderate-tosevere dyspnea has high prevalence, independently from the degree of oxygenation impairment, similarly to non-COVID 19 moderate-to-severe respiratory failure [1] . Presence of moderate-to-severe dyspnea might be a marker of disease severity correlated to outcomes, possibly configuring a clinical sub-phenotype of COVID-19 severe respiratory failure. Use of noninvasive support in COVID-19 patients is common [9] [10] [11] [12] . While considering a trial of noninvasive respiratory support in COVID-19 patients with moderate-to-severe respiratory failure, the presence of dyspnea, measured during conventional oxygen therapy, in conjunction with other variables such as respiratory rate and degree of hypoxia may represent a simple alert tool to identify patients with the highest risk of endotracheal intubation. FiO2 denotes fraction of inspired oxygen. PaCO2 partial pressure of arterial carbon dioxide, and PaO2 partial pressure of arterial oxygen. § The body-mass index is the weight in kilograms divided by the square of the height in meters. § § Discomfort was assessed through visual analog scales adapted for intensive care unit patients ranging from 0 to 10 § § § Allocated treatment refers to the advanced respiratory support interface used in the first 48 hours. For non-normal quantitative variables comparison between groups was performed with Mann-Whitney test. Comparison between groups for qualitative variables were performed with the Chi-Squared test or the Fisher's exact test, as appropriate in agreement with tests assumptions. All the calculations were unadjusted. Respiratory support: invasive or noninvasive mechanical ventilation, high-flow nasal oxygen. † One patient was discharged from hospital but died upon readmission. Groupe de Recherche en Reanimation Respiratoire du patient d'Onco-Hematologie (GRRR-OH). Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: A prospective observational study Why COVID-19 Silent Hypoxemia Is Baffling to Physicians Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure: The HENIVOT Randomized Clinical Trial Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire Dyspnea and respiratory muscles ultrasound to predict extubation failure Respiratory drive in the acute respiratory distress syndrome: pathophysiology, monitoring, and therapeutic interventions Respiratory Drive in Critically Ill Patients. Pathophysiology and Clinical Implications Noninvasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS. Intensive Care Med Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection High Failure Rate of Noninvasive Oxygenation Strategies in Critically Ill Subjects With Acute Hypoxemic Respiratory Failure Due to COVID-19 We are grateful to all intensive care unit physicians, residents, nurses, and personnel from the participating centers, whose sacrifice, efforts, devotion to patients, and passion have made possible this timely report.